Tin tức & Cập nhật
Xem bài viết Gan
Xem
Chỉ hiển thị Multimedia
Seladelpar improves liver outcomes in cirrhosis patients with PBC, portal hypertension
21 Jun 2026
bởiStephen Padilla
Treatment with seladelpar for 4 years yields consistent biochemical efficacy, with no new safety concerns, among patients with cirrhosis and primary biliary cholangitis (PBC), as shown by interim results from the open-label ASSURE study.
Seladelpar improves liver outcomes in cirrhosis patients with PBC, portal hypertension
21 Jun 2026
FMT reduces alcohol cravings, relapse rates in patients with ALD
16 Jun 2026
bởiElvira Manzano
Faecal microbiota transplantation (FMT) significantly improves alcohol abstinence and reduces relapse episodes for up to 6 months in patients with alcohol-related liver disease (ALD) and alcohol use disorder (AUD), as shown in a recent study presented at EASL 2026.
